Posit Science applies proprietary technology, based on established principles of brain plasticity, to address neurological disorders and to enhance human performance. Initially, the company is focused on developing software-based technology to arrest and reverse age-related cognitive decline and its progression to Mild Cognitive Impairment and Alzheimer’s Disease. Cognitive Decline. Virtually everyone experiences decline in cognitive abilities as they age. This may begin with occasional forgetfulness in one’s 30s, with the rate of decline accelerating significantly after age 50. Those with more advanced forms of cognitive decline are even less fortunate. It is estimated that approximately 23% of those over the age of 65 have Mild Cognitive Impairment, and that nearly half (47%) of those over 85, suffer from Alzheimer’s Disease.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 01/03/06 | Series B | 16.8M | Aberdare Ventures, DFJ, VSP Capital | Unknown |